New combo therapy tested for tough-to-treat cancers
NCT ID NCT05867121
First seen Nov 05, 2025 · Last updated Jun 14, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug (RO7496353) combined with an immunotherapy (checkpoint inhibitor) and sometimes chemotherapy in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participants will take part, and the study is not currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
Milan, Lombardy, 20162, Italy
-
Ankara City Hospital
Ankara, 06800, Turkey (Türkiye)
-
Asan Medical Center
Seoul, 05505, South Korea
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Centro Ricerche Cliniche Di Verona
Verona, Veneto, 37134, Italy
-
Clinica Universidad de Navarra-Madrid
Madrid, 28027, Spain
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Dokuz Eylul Universitesi Tip Fakultesi
Lzmir, 35340, Turkey (Türkiye)
-
Flinders Medical Centre
Bedford Park, South Australia, 5042, Australia
-
Fondazione Policlinico Universitario A Gemelli
Rome, Lazio, 00168, Italy
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
-
Hospital de Câncer de Barretos
Barretos, São Paulo, 14784-400, Brazil
-
Kanagawa Cancer Center
Kanagawa, 241-8515, Japan
-
NEXT Oncology-Hospital Quironsalud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
Samsung Medical Center - PPDS
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System - Clinical Trials Center Pharmacy
Seoul, 120-752, South Korea
-
Shizuoka Cancer Center
Shizuoka, 411-8777, Japan
-
St Vincent'S Hospital
Darlinghurst, New South Wales, 2010, Australia
-
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Tokyo, 135-8550, Japan
-
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, 06591, South Korea
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA University of California Los Angeles
Los Angeles, California, 90095, United States
-
Yale School of Medicine
New Haven, Connecticut, 06510-3206, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.